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Background. Bilateral lung volume reduction is designed to improve pul- 
monary function in selected patients with severe mphysema by improving 
diaphragmatic and chest wall mechanics. Early results of lung volume 
reduction suggest significant improvement toselected patients with chronic 
obstructive pulmonary disease, some of whom might otherwise be consid- 
ered for lung transplantation. The purpose of this review was to compare 
intermediate results of volume reduction with single and bilateral lung 
transplantation. Methods. Functional performance and survival after vol- 
ume reduction were compared with single and bilateral sequential lung 
transplantation. After evaluation, patients were enrolled in a supervised 
intensive preoperative and postoperative program of pulmonary rehabili- 
tation. Functional assessment, including pulmonary function tests, room 
air arterial blood gas analysis, and 6-minute walk distance, was obtained 
before the operation and 3, 6, and 12 months after the operation. Results. 
Thirty-three patients underwent volume reduction (mean age 57 years), 
39 patients single lung transplantation (55 years), and 27 patients bi- 
lateral lung transplantation (49 years). Early mortality was 0, 1 of 39, 
and 2 of 25 and mortality at 12 months was 1 of 33, 4 of 39, and 4 of 25 
in the volume reduction, single, and bilateral lung transplantation 
groups, respectively. At 6 months, mean forced expiratory volume in 
1 second was improved by 79% (volume reduction), by 231% (single lung 
transplantation), and by 498% (bilateral ung transplantation) over pre- 
operative values. Exercise endurance as measured by 6-minute walk 
distance increased by 28% (volume reduction), by 47% (single lung 
transplantation), and by 79% (bilateral lung transplantation) from 
baseline. At 6 months, all patients having single or bilateral lung 
transplantation and 26 of 33 patients having volume replacement were 
free of supplemental oxygen. Conclusions. Although single and bilateral 
lung transplantation result in superior lung function, volume reduction 
achieves satisfactory improvement of disabling symptoms early after 
operation while avoiding immunosuppression a d transplant-specific 
complications. Our experience suggests that (1) volume reduction is 
a suitable alternative in selected patients eligible for transplantation; 
(2) volume reduction provides an earlier option for treatment in 
patients who may require transplantation at some future date; (3) 
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volume reduction is the only surgical treatment available to the many 
patients who are not current or future transplant candidates. Conversely, 
in patients not suitable for volume reduction, transplantation remains the 
only choice for surgical therapy. (J TnORAC CARDIOVASC SURG 1996;111: 
296-307) 
D uring the past decade pulmonary transplantation has evolved into a successful treatment for patients 
with end-stage mphysema. Patients with chronic ob- 
structive pulmonary disease (COPD) constitute the 
single largest group of lung transplant recipients. 
Among recipients with emphysema, single and bilat- 
eral lung transplantation are associated with satisfac- 
tory early morbidity and mortality. 1 In addition, signif- 
icant physiologic improvement is achieved. 2 However, 
a critical shortage of suitable donor lungs restricts the 
transplant option to a small number of eligible pa- 
tients. Furthermore, many patients with COPD are 
considered ineligible for lung transplantation because 
of age or other comorbid conditions uch as coronary 
artery disease. Most lung transplant recipients have 
significant morbidity as a result of the mandatory 
immunosuppressive protocol. Long-term survival con- 
tinues to be adversely affected by chronic rejection 3 
and other complications. Because these limitations are 
expected to persist, alternate treatment s rategies are 
desirable in patients with diffuse emphysema. 
The concept for surgical reduction of lung volume 
was reported previously by Brantigan, Mueller, and 
Kress. 4 Recent advances in pulmonary rehabilitation, 
anesthetic technique, and surgical instrumentation 
have made surgery for reduction of bilateral ung 
volume a practical alternative. 5 Ideal candidates for 
volume reduction have (1) significant thoracic hyper- 
inflation with a flattened iaphragm and decreased 
chest wall excursion and (2) regions of severe destruc- 
tion that occupy a large volume with little perfusion, 
providing target areas for resection. The term volume 
reduction has been applied to this procedure because it
consists of multiple wedge resections (20% to 30% of 
lung volume bilaterally) and results in a reduced total 
lung capacity and radiographically measurable im- 
provement of chest wall distention and diaphragmatic 
excursion. 1 These improvements in turn improve ven- 
tilation to the more normal, although less compliant, 
regions of the lung. Although the patient is left with 
emphysematous l ngs, the postoperative problems of 
transplantation, i  particular ejection and immuno- 
suppression, are avoided. 
Our patient selection criteria for lung transplan- 
tation obviously include the absence of alternative 
therapy. The preliminary results from volume reduc- 
tion suggest that this procedure may offer significant 
improvement to some of the patients with COPD 
who might otherwise be considered for lung trans- 
plantation. The purpose of this review was to deter- 
mine whether the early results of lung volume 
reduction justify its use as an alternative to lung 
transplantation, even if the improvement after vol- 
ume reduction proves to be of limited duration. 
Selection criteria for lung transplantation a d vol- 
ume reduction are not identical. No attempt is 
therefore made to identify the "better" operation, 
but rather to provide a preliminary assessment of 
their relative roles in the treatment of patients with 
emphysema. 
Methods 
This report is a retrospective analysis of our results after 
three surgical procedures for advanced COPD: volume 
reduction, single lung transplantation, and bilateral se- 
quential lung transplantation. Patients with al-antitrypsin 
deficiency were excluded from this analysis, because we 
have only recently applied volume reduction to patients 
with this condition and sufficient follow-up for analysis is 
not yet available. Volume reduction was introduced at our 
institution in January 1993. With increasing experience, 
we offered volume reduction to patients who, by virtue of 
age less than 65 years and forced expiratory volume in 1 
second (FEV1) less than 20% of predicted,might other- 
wise have been eligible for lung transplantation. I deed, 
five of the patients in the volume reduction group (de- 
scribed in the next section) were listed for lung transplan- 
tation. The first such patient underwent volume reduction 
in December 1993. We have restricted this analysis to 
patients in whom postoperative follow-up for at least 6 
months is available. 
Volume reduction. Patients with advanced, iffuse em- 
physema nd severe exercise restriction were evaluated. 
Criteria important for selection were severe dyspnea, 
distention of the thorax, and heterogeneous di tribution 
of disease, typically with predominant destruction of the 
upper lobes. These conditions provide the opportunity of
"downsizing" lungs without sacrificing functioning lung 
tissue. All patients were judged to have residual lung with 
relatively preserved architecture. Patients with complete 
destruction of the entire lung were not offered volume 
reduction. At the current ime, we are uncertain as to 
exact selection criteria with regard to spirometric values, 
diffusing capacity, hypoxia, or hypercarbia. However, we 
believe that patients with an FEV1 iess than 15% of 
predicted, marked hypoxemia (necessitating more than 6 
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L of supplemental oxygen at rest), or severe hypercarbia 
(arterial carbon dioxide tension > 55 mm Hg) usually 
have such a degree of parenchymal lung destruction that 
volume reduction is not advisable. Patients were excluded 
from consideration i the presence of pulmonary hyper- 
tension (mean pulmonary artery pressure > 35 mm Hg, 
systolic pulmonary artery pressure > 45 mm Hg), severe 
kyphosis, severe left ventricular dysfunction, previous 
pleurodesis, age older than 80 years, asthma, severe 
chronic bronchitis, or bronchiectasis. Evaluation included 
inspiratory and expiratory posteroanterior and lateral 
chest radiographs, chest computed tomographic s intigra- 
phy, and quantitative nuclear ventilation-perfusion scin- 
tigraphy. Additional assessment consisted of pulmonary 
function studies, arterial blood gas analysis with the 
patient breathing room air, 6-minute walk distance, and 
dyspnea index (discussed later). Suitable candidates were 
enrolled in a supervised exercise program for at least 6 
weeks before the operation. A clear rehabilitation goal 
was set for each patient. With few exceptions, the opera- 
tion was not performed unless this goal had been met. 
Bilateral volume reduction was performed through a 
median sternotomy as previously described. 5 
Ninety patients underwent volume reduction between 
January 1993 and April 1995. Thirty-three of these have 
completed more than 6 months of follow-up and comprise 
the volume reduction group in this report. Eighteen of 
these 33 patients have completed more than 1 year of 
follow-up. Among all patients undergoing volume reduc- 
tion before February 1995, we identified five patients who 
were actually listed for transplantation and seven who 
were considered for transplantation but instead were 
referred to us for volume reduction. Data from these 12 
patients will be presented separately in this article. 
Lung transplantation. Patients were Selected for lung 
transplantation according to previously published crite- 
ria. 6 These criteria were more strict than those for volume 
reduction with regard to age (<65 years), cardiac perfor- 
mance (absence of significant left Ventricular dysfunction 
or coronary artery disease), and nonpulmonary organ 
dysfunction. Graded exercise training (discussed later) 
was instituted at the time of listing for transplantation. 
The conduct of this training was identical to that used 
before volume reduction, but its duration was usually 
longer because of the wait for a donor organ. Recipients 
were allocated to single or bilateral transplantation ac- 
cording to age, body size, and lung donor availability. 
Between March 1989 and April 1994, 64 patients un- 
derwent lung transplantation for COPD. Thirty-nine pa- 
tients had single lung transplantation performed via pos- 
terolateral thoracotomy. Twenty-five patients underwent 
bilateral sequential lung transplantation via bilateral an- 
terior thoracosternotomy. Standard techniques of donor 
harvest 7 and allograft implantation s, 9 were used. Immu- 
nosuppression consisted of cyclosporine, corticosteroid, 
azathioprine, and induction therapy with antilymphocyte 
globulin. These single and bilateral ung transplant recip- 
ients do not represent an experience contemporaneous 
with the patients undergoing volume reduction; rather, 
they are a group of consecutive patients in whom at least 
6 months of follow-up was available at the time of analysis. 
Pulmonary rehabilitation. Preoperative pulmonary re- 
habilitation was instituted to improve exercise endur- 
ance. 1° Patients exercised on the treadmill or on a bicycle 
ergometer three to five times per week to achieve 30 
minutes of continuous exercise at a heart rate of 85% of 
the predicted maximum heart rate for the patient's age. 
Supplemental oxygen was administered as necessary to 
maintain oxygen saturations of greater than 90% during 
exercise. Arm ergometry served to condition upper ex- 
tremity strength as needed and was used as an alternative 
to the treadmill for patients whose gait was limited by 
peripheral vascular disease or orthopedic/arthritis prob- 
lems. 
Postoperative pulmonary rehabilitation was used to 
restore exercise capacity, assist in airway clearance, and 
increase chest wall mobility. Short walks were resumed 
during the first postoperative days. When the patient was 
able to walk 2000 to 3000 feet per day after the operation, 
treadmill exercise was resumed. After volume reduction, 
patients continued their pulmonary rehabilitation pro- 
gram at our pulmonary rehabilitation facility for 1 week 
after discharge. Thereafter, rehabilitation was continued 
in the patients' own community. Lung transplant recipi- 
ents attended our rehabilitation facility five times per 
week for 3 months after discharge before returning to 
their own community program. 
Follow-up studies. Follow-up pulmonary function stud- 
ies, analysis of arterial blood gases with the patient 
breathing room air, and determination of 6-minute walk 
distance were obtained at 3-, 6-, and 12-month intervals. 
The oxygen requirements atrest and during exercise were 
recorded. 
At the time of evaluation, the degree of dyspnea was 
assessed with the use of the baseline part of the dyspnea 
index published by Mahler and associates. 11This index 
consists of three descriptive components. Functional im- 
pairment deals with performance in daily social and pro- 
fessional activities, magnitude oftask grades the load that 
leads to shortness of breath, and magnitude ofeffort grades 
the individual degree of exertion that results in dyspnea. 
Every component has grades ranging from 0 to 4, and the 
final score adds the three grades from each component. 
The baseline dyspnea index has a potential score from 12 
(no impairment) to 0 (severe impairment). 
Statistical analysis. Data were analyzed by means of a 
repeated-measures analysis of variance with the SAS 
program. 12 Selected time and group differences were 
investigated with pairwise t tests on the least-squares 
means. 
Results 
Patients in all three groups were profoundly re- 
stricted by their disease, although the degree of 
physiologic impairment was less severe in the vol- 
ume reduction (VR) group than in the single lung 
(SLT) or bilateral lung transplant (BLT) groups. 
Patients undergoing volume reduction had a higher 
mean FEV1, a longer walk distance in 6 minutes at 
the time of evaluation and after preoperative pul- 
monary rehabilitation (VR, 1"131 feet; SLT, 1036; 
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Table I. Patient profile at evaluation 
Volume Single lung Bilateral lung 
reduction transplantation transplantation 
No. of patients 33 39 25 
Mean age lyr) 57 55 49 
Male/female 17:16 11:28 10:15 
FEV I (L) 0.72 (_+0.26) 0.48 (_+0.12) 0.49 (_+0.13) 
FEV 1 (% of predicted) 25 (+7.3) 18 (_+3.9) 16 (_+4.5) 
FVC (L) 2.25 (+_0.82) 1.70 (_+0.60) 1.83 (_+0.79) 
FVC (% of predicted) 63 (_+19) 47 (_+12) 47 (_+17) 
Pao 2 (ram Hg Fio 2 0.21) 62 (_+9.7) 52 (_+9.2) 56 (_+8.5) 
Paco 2 (ram Hg Fio 2 0.21) 42 (_+7.6) 49 (_+9.9) 46 (_+8.4) 
Six-minute walk distance (feet) 917 (_+351) 703 (_+254) 830 (_+309) 
Baseline dyspnea index 3.2 (1-6) 3.1 (0-6) 3.6 (0-6) 
Functional and blood gas data are expressed as mean values (-~ standard eviation). Pulmonary function data represent best values achieved, with or without 
a bronchodilator. FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity; Pao2, arterial oxygen tension; Fio2, inspired oxygen fraction; 
Paco2, arterial carbon dioxide tension. 
Table II. Early and late mortality after volume reduction, single, and bilateral ung transplantation 
Volume reduction Single lung transplantation Bilateral ung transplantation 
Early (<30 days) mor- 0% (0/33) 
tality 
Cause of death 
Late (30 day to 1 year) 3.0% (1/33)* 
mortality 
Cause of death Heart failure s/p CABG 
at 3 mo 
Total mortality 3.0% (1/33)* 
2.5% (1/39) 
Allograft failure 
7.7% (3/39) 
CsA-related neurotoxicity at 2 mo 
Aspiration pneumonia t 3 mo 
Lymphoproliferative disease at 3 mo 
10.2% (4/39) 
8.0% (2/25) 
Intraop. hemorrhage 
Myocardial infarction 
8.o% (2/25) 
Lymphoproliferative disease at 7 mo 
Hemolytic-uremic syndrome at 9 mo 
16.0% (4/25) 
*Follow-up to 1 year after volume reduction is available for 18 of 33 patients. 
S/P, Status post; CABG, coronary artery bypass grafting; CsA, cyclosporine. 
BLT, 974), higher room air oxygen tension, and 
lower oxygen requirement (Table I). Forty-five per- 
cent (15/33) of patients undergoing volume reduc- 
tion were oxygen-dependent at rest and 88% (29/33) 
with exercise. Nineteen of 33 patients (57%) under- 
going volume reduction were receiving oral steroids 
before the operation. Symptoms and limitations of 
dyspnea were similar for patients in all three groups. 
The mean baseline dyspnea index (VR, grade 3.3; 
SLT, 3.1; BLT, 3.6) indicated severe functional 
impairment (i.e., dyspnea occurring with light activ- 
ities) and inability to work. 
Patients on the transplant list accrued significant 
waiting periods. Recipients of bilateral ung grafts 
waited on average 8.3 months (SD* + 2.8 months) 
and single lung recipients 5.8 months (SD ___ 3.7 
months) for their operation. In contrast, patients 
having volume reduction were operated on a mean 
*SD = Standard deviation. 
of 2.6 months (SD +_ 1.6 months) after their evalu- 
ation. Patients on the transplant list began their 
exercise program after being listed and continued 
until the time of transplantation. These patients 
reached a plateau in their walk distance from 6 
weeks to 3 months after starting the program, with 
no further improvement of exercise ndurance de- 
spite continued training. 
Among the 33 patients undergoing volume reduc- 
tion, there were no operative (30 day) deaths. One 
in-hospital death occurred 3 months after volume 
reduction (3.0%). After single lung transplantation, 
there was one perioperative death (2.5%) and three 
late deaths within the first year for an overall 
mortality of 10.2%. Operative and 1-year mortality 
rates after bilateral ung transplantation were each 
8% (2/25), for a total mortality rate of 16%. Causes 
of death are listed in Table II. Mean hospital stay 
was 31 days (median 21 days) after single lung 
transplantation, 27 days (median 23 days) after 
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Fig. 1. FEVa before and after volume reduction (VR), single lung transplantation (SLT), and bilateral 
lung transplantation (BLT). At evaluation (*): VR versus SLT, p < 0.001; VR versus BLT, p < 0.001. At 
6 months (D), VR versus SLT, p < 0.001; VR versus BLT, p < 0.001. (+) VR Eval versus VR 6 mo, p < 
0.001. 
bilateral ung transplantation, and 16 days (median 
13 days) after volume reduction. 
The three procedures, volume reduction, single 
lung transplantation, and bilateral sequential lung 
transplantation, all resulted in improvement of 
physiologic parameters, exercise ndurance, and gas 
exchange. At 6 and 12 months from the operation, 
mean FEV 1 had increased over preoperative values 
by 79% and 83% in the volume reduction group, by 
231% and 212% in single lung transplant recipients, 
and by 498% and 518% in bilateral lung transplant 
recipients (Fig. 1). Fig. 2 depicts the percent of 
predicted FEV 1. A modest increase in forced vital 
capacity was observed, particularly in the bilateral 
lung transplant group, whereas the other patients 
showed a smaller increase (Fig. 3). 
The 6-minute walk distance at 6 months was 28% 
greater than the preoperative distance (postrehabili- 
tation) in the volume reduction group, 47% greater 
in the single lung transplant recipients, and 79% 
greater in the bilateral lung transplant recipients 
(Fig. 4). The postoperative exercise tolerance did 
not deteriorate in a W patient group during the 
1-year follow-up period. 
Hypoxemia was improved after all three proce- 
dures. Whereas patients undergoing volume reduc- 
tion had higher oxygen tensions while breathing 
room air and showed only a modest postoperative 
improvement, both single and bilateral ung trans- 
plantation caused markedly increased room air ox- 
ygen tensions at 3 months, with continued improve- 
ment in the group having bilateral transplantation 
(Fig. 5). With improved oxygenation, the use of 
supplemental oxygen decreased after operation. All 
patients awaiting lung transplantation were receiv- 
ing supplemental oxygen at rest. Only one patient, 
after single lung transplantation, required supple- 
mental oxygen at 3 months and no patients thereaf- 
ter. In the volume reduction group, 29 patients 
(88%) required supplemental oxygen at exercise and 
15 patients also required oxygen at rest. Although 
freedom from oxygen supplementation took longer 
to achieve after volume reduction, by 6 months only 
seven patients (21%) used oxygen during exercise 
and three at rest (Table III). One year after volume 
reduction, one of 18 patients (5.5%) was oxygen- 
dependent during exercise and none at rest. Lung 
transplantation also corrected preoperative hyper- 
carbia within 3 months after the operation. Carbon 
dioxide retention in the volume reduction group was 
less prevalent, although carbon dioxide tensions 
were significantly lowered after the operation (Fig. 
6). 
We separately analyzed the data from 12 patients 
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Fig. 2. Percent of predicted FEVI before and after volume reduction (VR), single lung transplantation 
(SLT), and bilateral lung transplantation (BLT). At evaluation (*): VR versus SLT, p < 0.05; VR versus 
BLT, p < 0.001. At six months (D), VR versus SLT, p < 0.001, VR versus BLT, p < 0.001. (+) VR Eva] 
versus VR 6 mo, p < 0.001. 
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Fig. 3. Forced vital capacity (FVC) before and after volume reduction (VR), single lung transplantation, 
(SLT), and bilateral lung transplantation (BLT). At evaluation (*): VR versus SLT, p < 0.001; VR versus 
BLT, p < 0.001. At 6 months (D), VR versus SLT, p < 0.001; VR versus BLT, not significant. (+) VR Eval 
versus VR 6 mo, p < 0.001. 
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Fig. 4. Comparison of 6-minute walk distance before and after volume reduction (VR), single lung 
transplantation (SLT), and bilateral lung transplantation (BLT). At evaluation (*): VR versus SLT, not 
significant; VR versus BLT, p < 0.05. At 6 months ([]), VR versus SLT, not significant; VR versus BLT, 
p < 0.001. (+) VR Eval versus VR 6 mo, p < 0.001. 
in the volume reduction group who by virtue of age 
and FEV 1 less than 20% were "transplant eligible," 
Ten patients have been followed up for 3 months 
and seven patients for 6 months after their opera- 
tion (Table IV). Preoperative FEV1 (0.55 L, 20% of 
predicted), 6-minute walk distance (1098 feet), and 
room air oxygen tension (64 mm Hg) in these 
patients were comparable with those of both trans- 
plant groups. Postoperative improvement as mea- 
sured by FEV1 and 6-minute walk distance in these 
12 patients paralleled that of the total volume 
reduction group. At 6 months, postoperative FEV1 
increased by 59% over preoperative baseline values 
and 6-minute walk distance by 33%. 
Discussion 
Transplantation a d volume reduction are suitable 
options in the treatment of selected patients with 
advanced emphysema. Transplantation leads to im- 
pressive improvement in physiologic measurements, 
exercise ability, and gas exchange. Although the im- 
provement in these parameters after volume reduction 
may be less dramatic, it is nonetheless ignificant and 
maintained in intermediate follow-up examinations. 
Although volume reduction does not restore normal 
exercise capability, it does remove limitations on rou- 
tine activities, usually with freedom from oxygen de- 
pendency. Our experience suggests that (1) volume 
reduction is a suitable alternative in selected patients 
eligible for transplantation; (2)volume reduction pro- 
vides an earlier treatment option in patients who may 
require transplantation at some future date; (3) vol- 
ume reduction is the only surgical treatment available 
to patients who are not current or future transplant 
candidates. There are patients who do not fulfill 
criteria for volume reduction and for whom transplan- 
tation remains the only choice for surgical therapy. It is 
important to note that the majority of patients with 
emphysema are not candidates for volume reduction 
or transplantation. As always, patient selection is crit- 
ical. 
The concept of downsizing a hyperinflated, em- 
physematous lung and delaying or avoiding trans- 
plantation rests on the assumption that volume 
reduction provides ymptomatic relief from dyspnea 
and its associated disability and that this therapeutic 
effect persists long enough to justify the risks of the 
operation. We have found that the beneficial re- 
sponse to volume reduction lasts for the duration of 
our limited follow-up. In selected patients who 
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Fig. 5. Comparison of arterial oxygen tension (Pao2) before and after volume reduction (VR), single lung 
transplantation (SLT), and bilateral ung transplantation (BLT). At evaluation (*): VR versus SLT, p < 
0.001; VR versus BLT, p < 0.05. At 6 months (E]), VR versus SLT, p < 0.001; VR versus BLT, p < 0.001. 
(+) VR Eval versus VR 6 too, p < 0.001. 
fulfilled transplant criteria, volume reduction also 
resulted in improvement comparable with that of 
the overall group of patients having volume re- 
duction. Provided this degree of improvement can 
be maintained over 2 to 4 years, volume reduction 
will evolve into an alternative or additional ther- 
apy for patients with emphysema, permitting a 
satisfactory quality of life and delaying or elimi- 
nating the need for a transplant operation in some 
patients. 
We are satisfied at present with our ability to 
identify the ideal candidate for volume reduction. 
Patients with severe thoracic hyperinflation, a flat- 
tened diaphragm, and an immobile chest wall have 
the greatest likelihood of improvement in diaphrag- 
matic and chest wall mechanics. Heterogeneity of
disease provides "target" areas for resection. Fur- 
thermore, we believe that preoperative reduced 
ventilation to the less diseased regions of lung 
contributes to impaired gas exchange and that post- 
operative redistribution of ventilation accounts for 
the improved arterial oxygen tension (reduced ven- 
tilation/perfusion mismatch) observed in our vol- 
ume reduction group. Selection of the larger group 
of patients with less than ideal criteria is not so 
clear. Severe hypoxemia, hypercarbia, or marked 
reduction in FEV 1 may exclude a patient from 
Table III. Oxygen requirement 
VR SLT BLT 
Preop. 
At rest 45% (15/33) 100% (39/39) 100% (25/25) 
With exercise 88% (29/33) 
3 mo 
At rest 12% (4/33) 2.5% (1/39) 0% 
With exercise 30% (10/33) 
6 mo 
At rest 9% (3/33) 0% 0% 
With exercise 21% (7/33) 
VR, Volume reduction; SLT, single lung transplantation; BLT, bilateral 
lung transplantation. 
volume reduction if only a moderate degree of 
hyperinflation or heterogeneity is present. 
In patients eligible for transplantation, volume 
reduction avoids the inevitable complications of 
cyclosporine, azathioprine, and corticosteroid im- 
munosuppression. Furthermore, it eliminates the 
necessary monitoring of rejection by periodic pul- 
monary function testing and transbronchial biopsy. 
Physiologic parameters of lung function are less 
improved by a pneumoplastic procedure. For a 
patient with a predicted preoperative FEV 1 of 15%, 
a postoperative improvement of79%, as achieved in 
our series, would result in a predicted FEV 1 of 27%. 
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Fig. 6. Comparison of arterial carbon dioxide tension (Paco2) before and after volume reduction (VR), 
single lung transplantation (SLT) and bilateral lung transplantation (BLT). At evaluation (*): VR versus 
SLT, p < 0.001; VR versus BLT, p < 0.05. At 6 months ([3), VR versus SLT, not significant; VR versus 
BLT, not significant. (+) VR Eval versus VR 6 mo, p < 0.05. 
Table IV 
Preop. 3 mo 6 mo 
(n = 12) (n = 10) (n = 7) 
FEV 1 (% predicted) 
Total VR 0.72 (25) 1.19 (43) 1.29 (45) 
VR-LT canal. 0.55 (20) 0.90 (34) 0.88 (32) 
6-min walk (ft) 
Total VR 1131 1345 1449 
VR-LT cand. 1098 1265 1457 
Po2 (mm Hg) 
Total VR 62 69 74 
VR-LT cand. 64 76 73 
FEV~, 6-minute walk distance, and room air arterial oxygen tension (Po2) 
in lung transplant (LT) candidates undergoing volume reduction (VR) 
compared with values in the total volume reduction group. 
Although this may be less than that achieved by 
transplantation, exercise tolerance as measured by 
6-minute walk distance in these patients was almost 
as good as after transplantation. However, in any 
particular patient he lower the preoperative FEV1, 
the more ideal with respect o all other criteria for 
volume reduction the candidate should be. 
Several investigators have demonstrated impair- 
ment of postoperative xercise tolerance in lung 
transplant recipients, which persists during the first 
2 years after the operation. 13' 14 This impairment 
was not due to reduced gas exchange or ventilation, 
Furthermore, diaphragmatic function was not found 
to be impaired after lung transplantation. 15 The 
limitations are thought o be related to peripheral 
factors and physical deconditioning. These findings 
indicate that transplant recipients do not make full 
use of their restored lung function and that even the 
smaller increment of spirometric improvement 
achieved by volume reduction may be sufficient in 
many patients to allow unlimited aily activities. The 
first patients who underwent volume reduction were 
as a group not as limited as the pretransplantation 
population, because we selected patients cautiously 
while the response to the operation was not thor- 
oughly known. Mean FEV 1 in patients operated on 
since then has dropped to 0.61 L (22% of predicted) 
and resembles that of the transplant population 
more closely. 
Patients with advanced emphysema re often 
severely limited by dyspnea long before their lung 
function has deteriorated to the point that they 
become transplant candidates. We have performed 
volume reduction for debilitating symptoms, even 
when the FEV 1 does not meet transplant criteria. 
Both FEV 1 and the degree of hypoxemia re used as 
important selection criteria in transplant candidates, 
but not in volume reduction. We believe that vol- 
ume reduction will not preclude subsequent trans- 
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plantation, although we have not yet performed 
transplantation i a patient who has undergone 
volume reduction surgery. We have successfully 
performed transplantation i many patients with 
fibrous obliteration of the pleural space as a result of 
underlying disease or previous thoracic surgery. We 
anticipate that technical difficulty encountered after 
volume reduction surgery will be similar. Volume 
reduction may therefore prolong life and may even 
be used as a means to delay transplantation. A 
delayed transplant date also offers the hope of 
improved immunosuppression n the future. 
Many patients with diffuse emphysema re not 
candidates for transplantation because of age or 
coexisting disease. For these patients, volume reduc- 
tion is the only surgical therapy offering palliation. 
Of the 33 patients in our study, 12 were not eligible 
for transplantation because of age and two because 
of coexisting disease. Almost half of our patients 
(42%) therefore had no alternative other than con- 
tinued medical therapy. These were all patients who 
met the other selection criteria for volume reduc- 
tion, that is, hyperinflation or severe heterogeneity 
of disease. We have demonstrated that in carefully 
selected patients volume reduction can be con- 
ducted with safety and with the expectation of 
satisfactory functional results. 
Many patients with emphysema do not fulfill 
criteria for volume reduction. We advise against he 
operation in the presence of uniformly severe pa- 
renchymal destruction, inasmuch as this will likely 
result in an inferior outcome. This is particularly 
true for patients without hyperinflation who have 
preserved iaphragmatic excursion. In addition, pa- 
tients with other coexisting lung abnormalities, 
bronchitis, bronchiectasis, and prior thoracic proce- 
dures are poor candidates for bilateral volume re- 
duction surgery. 
Our preliminary experience indicates that in se- 
lected patients volume reduction is an effective 
treatment s rategy. It provides auseful alternative to 
lung transplantation in some cases. Indeed in many 
respects it is a preferable option. We await with 
interest the results of longer term follow-up in these 
patients. 
We thank Mary Pohl, RN, for her contribution to the 
collection and preparation of data on the volume reduc- 
tion experience, Dorothy Biggar, RN, for providing infor- 
mation on exercise performance in the transplant and 
volume reduction groups, Jennifer Manley, RN, for assist- 
ing with information on transplant recipients, Brad Wil- 
son for statistical assistance, and Mary Ann Kelly for her 
help in the preparation of the manuscript. 
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Discuss ion 
Dr. Joseph I. Miller (Atlanta, Ga.). One year ago in 
New York Drs. Cooper and Patterson presented a land- 
mark paper on the surgical management of emphysema, 
revitalizing Brantigan's operation of lung volume reduc- 
tion for emphysema. It is appropriate that 1 year later 
their functional results be reported. I would like to make 
several comments, raise two questions, and point out two 
areas of potential concern. 
The authors have correctly identified the ideal patient 
as one with hyperinflation, a flattened diaphragm, and 
target areas of heterogenicity of generalized emphysema, 
the so-called gas-trapping areas. It is important hat we 
remember this principle as we head into the third year of 
the reemergence of this operation. 
Physiologic improvement is believed to be due to 
improvement of chest wall mechanics by a restoration of 
diaphragmatic function and improved elastic recoil of the 
lung. 
In the selection process for lung volume reduction, the 
authors have not defined limits in regard to spirometric 
values, hypoxia, or hypercarbia. In the original presenta- 
tion by Dr. Cooper, the mean carbon dioxide tension was 
approximately 44 mm Hg with a high of 54 mm Hg. In 
visiting our institution, Dr. Cooper recently commented 
that he had operated on a number of patients with a 
carbon dioxide tension in the 70s. 
I believe that the audience should not go away thinking 
that hypercarbia and age are not significant factors in the 
preoperative s lection process. The majority of complica- 
tions occur in the hypercarbic group with a carbon dioxide 
tension greater than 50 mm Hg and an age greater than 70 
years. I would caution surgeons to be extremely careful in 
the selection process regarding these two parameters. To 
date, we have limited ourselves to a cutoff of 50 mm Hg 
for carbon dioxide tension and 75 years for age. 
The rehabilitation goals--being able to achieve a tar- 
geted goal of 30 minutes on the bicycle and 30 minutes on 
the treadmill--cannot be overemphasized. Conditioning 
is perhaps the most important aspect of the entire pro- 
gram. 
Dr. Gaissert has shown improvement in the three 
groups in terms of dyspnea index, spirometric values, and 
6-minute walk. In each, the functional results in the 
transplant groups were better than those in the lung 
volume reduction group, the functional results being 
approximately 50% in the lung volume reduction group 
compared with the transplant groups. 
The authors have correctly pointed out that lung vol- 
ume reduction avoids the long-term complications of 
immunosuppression, a d it may be an alternative surgical 
therapy for some individuals who are not candidates for 
transplantation. The cost differential alone is not insignif- 
icant. In our own locale, the average cost of single lung 
transplantation is $200,000 to $225,000. The average cost 
of our first 10 lung volume reduction operations was 
approximately $55,000, and this does not take into ac- 
count the $25,000 to $30,000 a year in immunosuppressive 
drugs required. 
In terms of functional results, our own data support 
those of Dr. Gaissert and his colleagues in St. Louis. 
Indeed our program is modeled entirely after the St. Louis 
program. Among our first 20 patients we obtained fol- 
low-up to 6 months in only four. However, the spirometric 
values, the oxygenation, and the 6-minute walk results are 
almost identical, showing that the results are easily repro- 
ducible, as pointed out by Dr. Gaissert. 
There have been a number of late-night calls among 
those of us doing this type operation as we go through 
previously uncharted postoperative waters. The problems 
have included panic attacks, distended colon and cecum, 
and the development ofpulmonary hypertension and right 
heart failure in patients with previously acceptable values. 
I have two questions. The authors tate that they advise 
against surgery in the presence of uniformly severe paren- 
chymal disease. I assume that they mean a lack of defined 
target areas on perfusion scanning. If I am not mistaken, 
a number of patients in their first 20 had uniform gener- 
alized emphysema with fairly equal perfusion distribution 
between left and right sides and between upper and lower 
lobes. Will the authors please clarify their statement that 
they have operated on a few of these with equal distribu- 
tion with fairly good results? 
Second, I would like to know the type of complications 
the authors have noted. 
I conclude with these two statements. This is a new and 
exciting operation, and I hope it will pass the 2-year time 
test that I think most Qf us believe will be a benchmark in 
determining its value. 
Second, I would caution against starting out on this type 
of operation without appropriate backup resources. The 
postoperative course of these patients is totally uncharted 
waters and presents complications that I have not seen in 
my 21-year practice experience. We can proceed with 
cautious optimism inasmuch as the initial results are 
highly encouraging; however, this type of lung volume 
reduction program should not be undertaken lightly. 
Dr. Gaissert. I thank Dr. Miller for his comments. Panic 
attacks have been seen by the residents taking care of 
these patients, but I think they are probably related to 
shortness of breath and to the postoperative strain. These 
patients require close, careful attention after the opera- 
tion and do not at all compare with patients who have had 
lobectomy or pneumonectomy. 
We believe that an even distribution of ventilation and 
perfusion certainly should raise the caution of the sur- 
geon. If any other indicators in that particular patient 
speak against surgical treatment, such as an elevated 
carbon dioxide tension or a severe degree of hypoxemia, 
we would certainly refrain from considering the patient 
for volume reduction. However, we would not regard 
ventilation-perfusion distribution as a contraindication to 
performing the operation so long as the anatomic riteria 
were fulfilled. 
Dr. Randas J. V. Batista (Campina Grande do Sul, 
Brazil). We share the same philosophy of volume reduc- 
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tion for improvement in organ function, but we apply the 
principle to the heart. Allow me to describe the case of a 
74-year-old man with Chagas' disease in whom we re- 
duced the volume of the heart. 
The patient had a very low ejection fraction that would 
have indicated heart transplantation had he not been too 
old for that operation. After cardioversion, a ventriculo- 
gram was obtained, which showed a high peripheral 
vascular resistance. He was receiving a high dose of 
inotropic agents, so we transferred him to the operating 
room on an emergency basis. 
We start our incision in the apex of the heart and extend 
it to the anterior papillary muscle, which is irrigated by the 
diagonal branch, and then to the mitral anulus. Thus we 
reduce the volume of the heart to improve function, just 
as you reduce the volume of the lung. The second incision 
involves excision. We excise through the apex of the heart, 
going down to the base of the posterior papillary muscle, 
which is irrigated by the circumflex branches, and finish 
the excision at the mitral valve. At that point we find live 
muscle, not scar tissue. The marginal artery emerges in 
this piece of muscle, and lots of clots are seen. We can 
excise more muscle in the anterior area. We do not 
crossclamp the aorta. 
We use through-and-through full-thickness utures (2-0 
Prolene sutures; Ethicon, Inc., Somerville, N.J.) in two 
layers. The first layer is to hold the muscles together, and 
the second layer is to provide hemostasis. If mitral repair 
is necessary, there is good exposure to repair the papillary 
muscles. In the past 11 years we have used this operation 
in 130 patients. 
At the end of the operation the patient described here 
was no longer receiving inotropic agents, he was starting 
to urinate, and peripheral perfusion was good. The only 
cardiac medication that he is taking in the postoperative 
period is nitroprusside (Nipride). 
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